CERUS (CERS) stock: insider trades, news & valuation
Heavy sellingShare price and insider trades
CERUS insider trading at a glance (Oct 9, 2026): in the past 12 months, 0 insiders bought $0 and 6 sold $3.5M of CERS stock on the open market.
Get emailed when insiders cluster-buy stocks like CERS
Free alerts the day a new cluster buy is filed, plus the Monday report of the week's biggest insider trades.
Free · unsubscribe anytime · not investment advice · see a sample issue
CERS insider buying and selling by quarter
Open-market purchases (green, above the line) and sales (red, below), by trade date.
| Quarter | Bought | Purchases | Sold | Sales |
|---|---|---|---|---|
| Q4 2026 | — | 0 | — | 0 |
| Q3 2026 | — | 0 | $142K | 2 |
| Q2 2026 | — | 0 | $748K | 7 |
| Q1 2026 | — | 0 | $2.4M | 15 |
| Q4 2025 | — | 0 | $94K | 1 |
| Q3 2025 | — | 0 | — | 0 |
| Q2 2025 | — | 0 | — | 0 |
| Q1 2025 | — | 0 | $188K | 1 |
Valuation, profit and volume
Summary
Over the past 12 months, 0 CERUS CORP insiders reported open-market purchases totaling $0, while 6 insiders reported sales totaling $3.5M. 25 of 26 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.
Insider transactions
Open-market purchases and sales.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| Aug 17SEC | Chrystal JensenGeneral Counsel | Sell Plan | 30,000936,657 held (−3%) | $2.98 | $89K | -22.8% | — |
| Jul 20SEC | Vivek K JayaramanCEO | Sell Plan | 16,6662,232,211 held (−1%) | $3.16 | $53K | -27.2% | — |
| Jul 2SEC | William Mariner GreenmanCEO, President | Sell Plan | 101,9195,053,036 held (−2%) | $2.94 | $300K | -21.8% | — |
| Jul 2SEC | Vivek K JayaramanCOO | Sell Plan | 42,3591,694,348 held (−2%) | $2.94 | $125K | -21.8% | — |
| Jul 2SEC | Kevin Dennis GreenCFO | Sell Plan | 33,6761,062,188 held (−3%) | $2.94 | $99K | -21.8% | — |
| Jul 2SEC | Chrystal JensenGeneral Counsel | Sell Plan | 24,329966,657 held (−2%) | $2.94 | $72K | -21.8% | — |
| Jun 11SEC | Eric BjerkholtDirector | Sell | 20,454261,679 held (−7%) | $2.60 | $53K | -11.5% | — |
| Jun 2SEC | Vivek K JayaramanCOO | Sell Plan | 16,6671,656,707 held (−1%) | $3.00 | $50K | -23.3% | — |
| May 5SEC | Vivek K JayaramanCOO | Sell Plan | 16,6671,673,374 held (−1%) | $3.00 | $50K | -23.3% | — |
| Mar 16SEC | William Mariner GreenmanCEO, President | Sell Plan | 447,7574,998,493 held (−8%) | $1.66 | $743K | +38.6% | — |
| Mar 16SEC | Vivek K JayaramanCOO | Sell Plan | 165,2001,747,674 held (−9%) | $1.66 | $274K | +38.6% | — |
| Mar 16SEC | Kevin Dennis GreenCFO | Sell Plan | 127,5441,040,551 held (−11%) | $1.66 | $212K | +38.6% | — |
| Mar 16SEC | Chrystal JensenGeneral Counsel | Sell Plan | 113,008946,131 held (−11%) | $1.66 | $188K | +38.6% | — |
| Mar 16SEC | Richard J BenjaminChief Medical Officer | Sell Plan | 101,740777,361 held (−12%) | $1.66 | $169K | +38.6% | — |
| Mar 10SEC | Richard J BenjaminChief Medical Officer | Sell Plan | 61,233943,762 held (−6%) | $2.06 | $126K | +11.7% | — |
| Mar 10SEC | Richard J BenjaminChief Medical Officer | Sell Plan | 40,426879,101 held (−4%) | $1.88 | $76K | +22.3% | — |
| Mar 10SEC | Richard J BenjaminChief Medical Officer | Sell Plan | 24,235919,527 held (−3%) | $2.01 | $49K | +14.4% | — |
| Mar 9SEC | William Mariner GreenmanCEO, President | Sell Plan | 78,1875,446,250 held (−1%) | $2.01 | $157K | +14.4% | — |
| Mar 9SEC | Richard J BenjaminChief Medical Officer | Sell Plan | 61,233943,762 held (−6%) | $2.06 | $126K | +11.7% | — |
| Mar 9SEC | Kevin Dennis GreenCFO | Sell Plan | 55,2251,195,891 held (−4%) | $2.06 | $114K | +11.7% | — |
| Mar 9SEC | Richard J BenjaminChief Medical Officer | Sell Plan | 40,426879,101 held (−4%) | $1.88 | $76K | +22.3% | — |
| Mar 9SEC | Vivek K JayaramanCOO | Sell Plan | 34,0941,912,874 held (−2%) | $2.01 | $69K | +14.4% | — |
| Mar 9SEC | Chrystal JensenGeneral Counsel | Sell Plan | 30,8451,059,139 held (−3%) | $2.01 | $62K | +14.4% | — |
| Mar 9SEC | Kevin Dennis GreenCFO | Sell Plan | 27,7961,168,095 held (−2%) | $2.01 | $56K | +14.4% | — |
| Mar 9SEC | Richard J BenjaminChief Medical Officer | Sell Plan | 24,235919,527 held (−3%) | $2.01 | $49K | +14.4% | — |
| Nov 26SEC | Chrystal JensenGeneral Counsel | Sell Plan | 55,000728,294 held (−7%) | $1.70 | $94K | +35.3% | — |
Insiders at CERUS CORP
| Insider | Bought | Sold | Last filing | Score |
|---|---|---|---|---|
| William Mariner GreenmanCEO, President | — | $1.2M | Jul 2, 2026 | — |
| Richard J BenjaminChief Medical Officer | — | $671K | Mar 16, 2026 | — |
| Vivek K JayaramanCEO | — | $620K | Jul 20, 2026 | — |
| Chrystal JensenGeneral Counsel | — | $504K | Aug 17, 2026 | — |
| Kevin Dennis GreenCFO | — | $480K | Jul 2, 2026 | — |
| Eric BjerkholtDirector | — | $53K | Jun 11, 2026 | — |
CERS stock: common questions
Are CERUS CORP insiders buying CERS stock?
In the past 12 months, 0 insiders reported open-market purchases of CERS worth $0.
Are CERUS CORP insiders selling CERS stock?
6 insiders reported sales worth $3.5M over the same period.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.
What is CERS's 52-week range?
Over the past year CERS has traded between $1.40 and $3.28. It last closed at $2.30 on Oct 9, 2026.